Identification of targets and new developments in the treatment of multiple sclerosis-focus on cladribine

Clemens Warnke, Heinz Wiendl, Hans Peter Hartung, Olaf Stüve, Bernd C. Kieseier

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

Orally available disease-modifying drugs for relapsing-remitting multiple sclerosis (MS) represent an unmet need for this chronic and debilitating disease. Among 5 currently investigated drugs at phase 3 clinical stage, promising efficacy data for fingolimod and oral cladribine have recently been published. However, benefits need to be weighed against the risks to define the role of these compounds within current treatment regimens. In this review, data on the efficacy of a promising compound, oral cladribine, are discussed and balanced with known and anticipated risks in a postmarketing era, and finally gives an outlook on the potential place of this drug in treatment algorithms for MS in the future.

Original languageEnglish (US)
Pages (from-to)117-126
Number of pages10
JournalDrug Design, Development and Therapy
Volume4
StatePublished - Dec 1 2010

Keywords

  • Immunosuppressant
  • Oral drugs
  • Risk-benefit
  • Safety

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint Dive into the research topics of 'Identification of targets and new developments in the treatment of multiple sclerosis-focus on cladribine'. Together they form a unique fingerprint.

  • Cite this